amyloidosis


Also found in: Thesaurus, Medical, Financial, Encyclopedia, Wikipedia.
Related to amyloidosis: familial amyloidosis

am·y·loid·o·sis

 (ăm′ə-loi-dō′sĭs)
n.
Any of a group of diseases or conditions characterized by the formation and deposition of amyloid in various organs and tissues of the body.

amyloidosis

(ˌæmɪlɔɪˈdəʊsɪs)
n
(Pathology) pathol the deposition of amyloid in various tissues of the body, as occurs in certain chronic infections
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.amyloidosis - a disorder characterized by deposit of amyloid in organs or tissues; often secondary to chronic rheumatoid arthritis or tuberculosis or multiple myeloma
illness, sickness, unwellness, malady - impairment of normal physiological function affecting part or all of an organism
Translations

am·y·loi·do·sis

n. amiloidosis, acumulación de amiloide en los tejidos.

amyloidosis

n amiloidosis f
References in periodicals archive ?
Alnylam Pharmaceuticals shared new findings at the Second European Meeting of ATTR Amyloidosis, or EU-ATTR, for Doctors and Patients, being held September 2-3, in Berlin, Germany.
(NASDAQ: IONS), today announced that data from the NEURO-TTR open-label study along with data from the AKCEA-TTR-LRx program and additional clinical presentations on the efficacy and safety profile of TEGSEDI will be presented at the 2nd European ATTR Amyloidosis Alliance Meeting in Berlin, Germany, September 2-3, 2019.
Right now, almost 47 million cognitively normal people in the United States may have brain amyloidosis, the physical finding used to define preclinical Alzheimer's disease (AD).
Memorial donations may be made in Terry's name to the Amyloidosis Foundation at www.amyloidosis.org.
APML Overseas President Afzaal Siddiqui told DawnNewsTV that Musharraf had suffered a reaction from amyloidosis, a rare condition for which the former president has been receiving medical care.
Summary: Musharraf suffered a reaction from amyloidosis, a rare condition
Caelum Biosciences has signed a strategic agreement with Alexion Pharmaceuticals to advance the development of CAEL-101 for light chain (AL) amyloidosis.
Caelum Biosciences, a subsidiary of Fortress Biotech, has signed a strategic agreement with United States-based Alexion Pharmaceuticals to advance the development of CAEL-101 for light chain (AL) amyloidosis, a rare systemic disorder caused by an abnormality of plasma cells in the bone marrow, it was reported on Friday.
and Caelum Biosciences have collaborated to develop CAEL-101 for light chain (AL) amyloidosis. CAEL-101 is a first-in-class amyloid fibril targeted therapy designed to improve organ function by reducing or eliminating amyloid deposits in patients with AL amyloidosis.
In amyloidosis, abnormal proteins are deposited in tissues anywhere in the body.
Amyloidosis is a disease characterized by extracellular accumulation of amyloid protein in different organs and tissues.